Study
| Multicenter, multicohort, open-abel trial (GARNET) |
| dMMR recurrent or advanced endometrial cancer who had progressed on or after a platinum-containing regimen |
| Dostarlimab-gxly q21 (n=141) |
Efficacy
| ORR: 45.4% [37.0-54.0]; CR: 15.6%; PR:29.8% |
| 12 mos DOR: 85.9% |
| 24 mos DOR: 54.7% |
Safety
| Any grade AEs: Asthenia (40%), diarrhea (25%), anemia (25%), neutropenia (12%), skin rash (14%) |
BMJ 2022, 10 (1)
http://doi.org/10.1136/jitc-2021-003777
Reviewed by Elvin Chalabiyev, MD on Mar 15, 2023
